In $1.36B biobuck deal with GSK, Mersana touts 'biggest preclinical ADC deal ever' - Endpoints News

8/8/2022 12:00:00 AM2 years 8 months ago
by Kyle LaHucik

Days after Enhertu reeled in another FDA nod, with the first-ever green light for HER2-low breast cancer, another antibody drug conjugate biotech claims it has secured the largest preclinical ADC pact to date for a single asset. AstraZeneca and Daiichi Sankyo…

Days af­ter En­her­tu reeled in an­oth­er FDA nod, with the first-ever green light for HER2-low breast can­cer, an­oth­er an­ti­body drug con­ju­gate biotech claims it has se­cured the largest pre­cl… [+1059 chars]

full article...